Sascha A Tuchman
Overview
Explore the profile of Sascha A Tuchman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
422
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jensen C, Vohra S, Nyrop K, Deal A, LeBlanc M, Grant S, et al.
Oncologist
. 2022 May;
27(8):694-702.
PMID: 35511734
Background: The plasma cell disorders (PCDs), multiple myeloma (MM), and light-chain amyloidosis (AL) are disproportionately diseases of older adults, whose care may be complicated by frailty associated with advancing age....
12.
Nakamura Z, Vohra S, Jensen C, Nyrop K, Deal A, Heiling H, et al.
J Geriatr Oncol
. 2022 Apr;
13(7):987-996.
PMID: 35484067
Introduction: Older adults with plasma cell disorders (PCDs) experience cognitive dysfunction that may be attributable to the disease and associated therapies. Yet, this has seldom been reported in the literature....
13.
Gasparetto C, Schiller G, Tuchman S, Callander N, Baljevic M, Lentzsch S, et al.
Br J Cancer
. 2021 Nov;
126(5):718-725.
PMID: 34802051
Background: Proteasome inhibitors (PIs), including carfilzomib, potentiate the activity of selinexor, a novel, first-in-class, oral selective inhibitor of nuclear export (SINE) compound, in preclinical models of multiple myeloma (MM). Methods:...
14.
Voorhees P, Suman V, Tuchman S, Laubach J, Hassoun H, Efebera Y, et al.
Am J Hematol
. 2021 Sep;
96(12):1595-1603.
PMID: 34559902
Preclinical studies have demonstrated activity of the oral proteasome inhibitor (PI) ixazomib (IXA) in bortezomib-resistant multiple myeloma (MM) and synergy with immunomodulatory drugs. We therefore conducted a phase I/II study...
15.
Ramasamy K, Nooka A, Quach H, Htut M, Popat R, Liedtke M, et al.
Blood Cancer J
. 2021 Sep;
11(9):149.
PMID: 34480019
No abstract available.
16.
Jensen C, Vohra S, Nyrop K, Deal A, Muss H, Lichtman E, et al.
J Geriatr Oncol
. 2021 Aug;
13(2):182-189.
PMID: 34389255
Objectives: Findings from a brief geriatric assessment (GA) in a cohort of adults with multiple myeloma (MM) are presented, with particular attention to the utility of the GA in identifying...
17.
Usmani S, Karanes C, Bensinger W, DSouza A, Raje N, Tuchman S, et al.
Leukemia
. 2021 May;
35(12):3526-3533.
PMID: 34050260
Part B of this phase 1b study (ClinicalTrials.gov number, NCT02283775) evaluated safety and efficacy of a fixed-volume infusion of isatuximab, an anti-CD38 monoclonal antibody, in combination with pomalidomide and dexamethasone...
18.
Laubach J, Tuchman S, Rosenblatt J, Mitsiades C, Colson K, Masone K, et al.
Blood Cancer J
. 2021 Feb;
11(2):20.
PMID: 33563894
Additional therapeutic options are needed for relapsed and refractory multiple myeloma (RRMM). We present data from a phase 1b, open-label, dose-escalation study (NCT01965353) of 20 patients with RRMM (median age:...
19.
Tuchman S, Zonder J
Hematol Oncol Clin North Am
. 2020 Oct;
34(6):997-1008.
PMID: 33099435
The spectrum of immunoglobulin paraprotein-associated diseases requiring therapy extends beyond multiple myeloma and AL amyloidosis. Awareness of these is essential in ensuring timely accurate diagnosis and appropriate treatment. As most...
20.